- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
PCI (www.pcisynthesis.com), a Boston-based Contract Manufacturing Organization (CMO) that manufacturers new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and complex specialty chemicals, today announced the general availability of phosphonic acids, widely used by researchers and developers of nano-particle technology applications around the world, and the launch of its new web page phosphonicacid.com.
Ed Price, president of PCI, said, "More than 200 of our worldwide customers and academic partners use PCI's phosphonic acids today. Innovation and quality have long been hallmarks of PCI, and our phosphonic product line is the latest example."
PCI's growing industry reputation is reflected in its latest industry accolades: PCI just won four categories of the 2013 Life Science Leader CMO Leadership Awards for quality, innovation, productivity and reliability.
Phosphonic acids have wide commercial use as surfactants for the manufacture of a host of different nano-particle technologies, used in the electronics and alternative energy industries. Phosphonic acids also have unique properties as chelating agents that can be utilized in certain specific microelectronic applications as well. For more than 10 years PCI's phosphonic acids have been used widely by nanotechnology manufacturers, governments and research institutions around the world.
"We manufacture eight phosphonic acids today, available in small quantities such as 10g all the way up to several metric tons," concluded Price, "We have developed processes that produce these materials in very high purity and low metals content. We have also developed sophisticated analytical tools that allow us to analyze these materials."
About PCI Synthesis
PCI Synthesis is a 13-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals.
For more information, please click here
Copyright © MarketwireIf you have a comment, please Contact us.
|Related News Press|
News and information
Dais Analytic Unveils New Version of Aqualyte Membrane Technology: Updates to the Basis of the Company's Industry-Changing Nanotechnology Designed to Strengthen Position in Global Air, Energy, and Water Markets June 26th, 2015